Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: Effects of adalimumab versus placebo

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-5

  Tak, Paul P ^a   van Kuijk, Arno W R ^a   Degroot, Jeroen ^b   Koeman, Rishma C ^a   Sakkee, Nico ^b   Baeten, Dominique L ^a   Gerlag, Danielle M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINO TERMINAL CROSS LINKED TELOPEPTIDE OF TYPE 1 COLLAGEN; C PROPEPTIDE OF TYPE 2 COLLAGEN; CARBOXY TERMINAL CROSS LINKED TELOPEPTIDE OF TYPE 1 COLLAGEN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; OSTEOCALCIN; PLACEBO; PROCOLLAGEN; PROCOLLAGEN SERUM TYPE 1 AMINO TERMINAL PROPEPTIDE; STROMELYSIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ARTICLE; BONE METABOLISM; CARTILAGE CELL; CARTILAGE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DRUG EFFICACY; HUMAN; OSSIFICATION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; TISSUE METABOLISM; ADULT; AGED; BLOOD; BONE; CARTILAGE; FEMALE; MALE; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; BONE AND BONES; CARTILAGE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; YOUNG ADULT;

EID: 77958568433     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012556     Document Type: Article

References (38)

1. Rahman P, Nguyen E, Cheung C, Schentag CT, Gladman DD (2001) Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 28(5): 1041-1044.
2. Kane D, Stafford L, Bresnihan B, Fitzgerald O (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 42(12): 1460-1468.
3. Mease P (2004) TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 63(7): 755-758.
4. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 117(2): 244-279.
5. Gerlag DM, Tak PP (2008) Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. Best Pract Res Clin Rheumatol 22(2): 311-323.
6. van Kuijk AW, Gerlag DM, Vos K, Wolbink G, de Groot M, et al. (2009) A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis 68(8): 1303-1309.
7. Kruithof E, De Rycke L, Vandooren B, De Keyser F, Fitzgerald O, et al. (2006) Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum 54(6): 1795-804.
8. Landewe RB, Geusens P, van der Heijde DM, Boers M, van der Linden SJ, et al. (2006) Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis. Ann Rheum Dis 65(1): 40-44.
9. Degroot J, Zuurmond AM, Tak PP (2008) Biologic Markers. In: Firestein GS, et al. (2008) Kelley's textbook of rheumatology. pp 475-489.
10. Garnero P, Delmas PD (2004) Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers. Curr Opin Rheumatol 16(4): 428-434.
11. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, et al. (2003) The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18(5): 859-867.
12. Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC (2004) The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods 294(1-2): 145-153.
13. Landewe R, Geusens P, Boers M, van der HD, Lems W, et al. (2004) Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 50(5): 1390-1399.
14. Garnero P, Geusens P, Landewe R (2003) Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheumatol 21(5 Suppl 31): S54-S58.
15. Verstappen SM, Poole AR, Ionescu M, King LE, Abrahamowicz M, et al. (2006) Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther 8(1): R31.
16. Vis M, Wolbink GJ, Lodder MC, Kostense PJ, van de Stadt RJ, et al. (2003) Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. Arthritis Rheum 48(10): 2996-2997.
17. Mullan RH, Matthews C, Bresnihan B, Fitzgerald O, King L, et al. (2007) Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. Arthritis Rheum 56(9): 2919-2928.
18. Chopin F, Garnero P, Le HA, Debiais F, Daragon A, et al. (2008) Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67(3): 353-357.
19. Vandooren B, Kruithof E, Yu DT, Rihl M, Gu J, et al. (2004) Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50(9): 2942-2953.
20. Muller-Ladner U, Bosserhoff AK, Dreher K, Hein R, Neidhart M, et al. (1999) MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. Rheumatology (Oxford) 38(2): 148-154.
21. Vandooren B, Cantaert T, van Lierop MJ, Bos E, De Rycke L, et al. (2009) Melanoma Inhibitory Activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis. Ann Rheum Dis 68(6): 1044-1050.
22. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, et al. (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8): 2665-2673.
23. Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3(1): 55-78.
24. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1): 44-48.
25. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, et al. (2006) Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 65(10): 1373-1378.
26. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, et al. (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373(9664): 633-640.
27. Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, et al. (1995) Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 38(7): 969-975.
28. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, et al. (2000) Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43(4): 852-858.
29. Ribbens C, Porras M, Franchimont N, Kaiser MJ, Jaspar JM, et al. (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61(2): 161-166.
30. Garnero P, Landewe R, Boers M, Verhoeven A, van der Linden S, et al. (2002) Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 46(11): 2847-2856.
31. Tchetverikov I, Lard LR, DeGroot J, Verzijl N, TeKoppele JM, et al. (2003) Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 62(11): 1094-1099.
32. Roux-Lombard P, Eberhardt K, Saxne T, Dayer JM, Wollheim FA (2001) Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology (Oxford) 40(5): 544-551.
33. Green MJ, Gough AK, Devlin J, Smith J, Astin P, et al. (2003) Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 42(1): 83-88.
34. den Broeder AA, Joosten LA, Saxne T, Heinegard D, Fenner H, et al. (2002) Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 61(4): 311-318.
35. Jensen T, Klarlund M, Hansen M, Jensen KE, Skjodt H, et al. (2004) Connective tissue metabolism in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity, bone mineral density, and radiographic outcome. J Rheumatol 31(9): 1698-1708.
36. Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, et al. (2007) Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 56(10): 3236-3247.
37. Kruithof E, De Rycke L, Roth J, Mielants H, Van Den Bosch F, et al. (2005) Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 52(12): 3898-3909.
38. Maksymowych WP, Rahman P, Shojania K, Olszynski WP, Thomson GT, et al. (2008) Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 35(10): 2030-2037.